Needle Biopsy

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 219 Experts worldwide ranked by ideXlab platform

D. C. Strauss - One of the best experts on this subject based on the ideXlab platform.

  • Percutaneous Core Needle Biopsy in Retroperitoneal Sarcomas Does Not Influence Local Recurrence or Overall Survival
    Annals of Surgical Oncology, 2015
    Co-Authors: M. J. Wilkinson, J. L. Martin, A. A. Khan, A. J. Hayes, J. M. Thomas, D. C. Strauss
    Abstract:

    Background Tumours within the retroperitoneum can cause a diagnostic dilemma. A preoperative core Needle Biopsy often is required to establish a histological diagnosis. Preoperative core Needle Biopsy for extremity soft-tissue sarcoma is oncologically safe and Biopsy site recurrence is extremely rare, attributed to placing the Biopsy site within the planned resection field. This study investigates whether preoperative core Needle Biopsy affects oncological outcomes in retroperitoneal sarcomas. Methods Patients undergoing resection of intermediate- and high-grade primary retroperitoneal sarcoma from 1990 until 2011 were included. Primary endpoints were immediate Biopsy-related complications, local recurrence, and overall survival. Results A total of 150 patients were included in the analysis. Of these, 90 patients underwent resection after a preoperative Biopsy. Median follow-up was 48 months. One patient required hospital admission postBiopsy for an abdominal wall rectus sheath haematoma. No patient developed intra-abdominal complications that required hospitalisation or early operation related to core Needle Biopsy. No patient developed a Biopsy site recurrence. There was no significant increase in either local recurrence ( p  = 0.101) or overall survival ( p  = 0.191) after core Needle Biopsy. Conclusions Preoperative core Needle Biopsy for retroperitoneal sarcomas is safe and does not affect oncological outcome.

  • percutaneous core Needle Biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival
    Annals of Surgical Oncology, 2015
    Co-Authors: M. J. Wilkinson, J. L. Martin, A. A. Khan, A. J. Hayes, J. M. Thomas, D. C. Strauss
    Abstract:

    Background Tumours within the retroperitoneum can cause a diagnostic dilemma. A preoperative core Needle Biopsy often is required to establish a histological diagnosis. Preoperative core Needle Biopsy for extremity soft-tissue sarcoma is oncologically safe and Biopsy site recurrence is extremely rare, attributed to placing the Biopsy site within the planned resection field. This study investigates whether preoperative core Needle Biopsy affects oncological outcomes in retroperitoneal sarcomas.

M. J. Wilkinson - One of the best experts on this subject based on the ideXlab platform.

  • Percutaneous Core Needle Biopsy in Retroperitoneal Sarcomas Does Not Influence Local Recurrence or Overall Survival
    Annals of Surgical Oncology, 2015
    Co-Authors: M. J. Wilkinson, J. L. Martin, A. A. Khan, A. J. Hayes, J. M. Thomas, D. C. Strauss
    Abstract:

    Background Tumours within the retroperitoneum can cause a diagnostic dilemma. A preoperative core Needle Biopsy often is required to establish a histological diagnosis. Preoperative core Needle Biopsy for extremity soft-tissue sarcoma is oncologically safe and Biopsy site recurrence is extremely rare, attributed to placing the Biopsy site within the planned resection field. This study investigates whether preoperative core Needle Biopsy affects oncological outcomes in retroperitoneal sarcomas. Methods Patients undergoing resection of intermediate- and high-grade primary retroperitoneal sarcoma from 1990 until 2011 were included. Primary endpoints were immediate Biopsy-related complications, local recurrence, and overall survival. Results A total of 150 patients were included in the analysis. Of these, 90 patients underwent resection after a preoperative Biopsy. Median follow-up was 48 months. One patient required hospital admission postBiopsy for an abdominal wall rectus sheath haematoma. No patient developed intra-abdominal complications that required hospitalisation or early operation related to core Needle Biopsy. No patient developed a Biopsy site recurrence. There was no significant increase in either local recurrence ( p  = 0.101) or overall survival ( p  = 0.191) after core Needle Biopsy. Conclusions Preoperative core Needle Biopsy for retroperitoneal sarcomas is safe and does not affect oncological outcome.

  • percutaneous core Needle Biopsy in retroperitoneal sarcomas does not influence local recurrence or overall survival
    Annals of Surgical Oncology, 2015
    Co-Authors: M. J. Wilkinson, J. L. Martin, A. A. Khan, A. J. Hayes, J. M. Thomas, D. C. Strauss
    Abstract:

    Background Tumours within the retroperitoneum can cause a diagnostic dilemma. A preoperative core Needle Biopsy often is required to establish a histological diagnosis. Preoperative core Needle Biopsy for extremity soft-tissue sarcoma is oncologically safe and Biopsy site recurrence is extremely rare, attributed to placing the Biopsy site within the planned resection field. This study investigates whether preoperative core Needle Biopsy affects oncological outcomes in retroperitoneal sarcomas.

Jonathan I. Epstein - One of the best experts on this subject based on the ideXlab platform.

  • a contemporary study correlating prostate Needle Biopsy and radical prostatectomy gleason score
    The Journal of Urology, 2008
    Co-Authors: Samson W Fine, Jonathan I. Epstein
    Abstract:

    Purpose: We determined whether contemporary practice patterns of Gleason grading for prostate Needle Biopsy and radical prostatectomy have evolved.Materials and Methods: We correlated Needle Biopsy (assigned at Johns Hopkins Hospital and other institutions) and radical prostatectomy Gleason score for 1,455 men who underwent radical prostatectomy at Johns Hopkins Hospital from 2002 to 2003, and compared the results with those of a 1994 study of similar design.Results: Outside institutions diagnosed Gleason score 2–4 in 1.6% (23 of 1,455) of Needle biopsies vs 22.3% (87 of 390) in 1994. Of Needle biopsies labeled Gleason score 2–4, 30.4% revealed radical prostatectomy Gleason score 7–10. In 2002 to 2003 no Johns Hopkins Hospital Needle Biopsy was assigned Gleason score 2–4. Needle biopsies designated Gleason score 6 or less had 80.0% accuracy with regard to radical prostatectomy Gleason score vs 63% accuracy in older data. For Needle Biopsy Gleason score 7 or greater, 35.5% (outside institution) and 24.8% (...

  • incidence of high grade prostatic intraepithelial neoplasia in sextant Needle Biopsy specimens
    Urology, 1997
    Co-Authors: Marcia L Wills, Ulrike M Hamper, Alan W Partin, Jonathan I. Epstein
    Abstract:

    Abstract Objectives There is scant literature on the frequency of high-grade prostatic intraepithelial neoplasia (PIN) in Needle Biopsy specimens. These data have implications as to how often pathologists should be expected to diagnose these lesions on Needle Biopsy and impact on the feasibility of cancer chemoprevention trials for prostate cancer. Methods We reviewed 439 consecutive 18-gauge sextant Needle Biopsy specimens from the Johns Hopkins Hospital. Results Based on the pathology reports, high-grade PIN was recorded in 12 (2.7%) of the cases and was confirmed upon review. Following review of the slides, unequivocal high-grade PIN was found in an additional 6 cases. There were 6 other cases where the findings were borderline between high- and low-grade PIN, but which were believed to be more consistent with high-grade PIN. Considering these latter cases in conjunction with the unequivocal cases of high-grade PIN, the incidence of high-grade PIN was 5.5% (24 of 439). Conclusions Recognizing that approximately 50% of men with high-grade PIN on Needle Biopsy will be found to have carcinoma on repeat Biopsy, the management of high-grade PIN on Biopsy will only apply to 50% of the men initially discovered with this finding. If only 2.75% of men who are biopsied eventually need therapy for high-grade PIN on Needle Biopsy, the number of cases needed to study the decrease of high-grade PIN following chemoprevention might be prohibitively high. If the incidence of high-grade PIN on Needle Biopsy requiring therapy is only 2.75%, it may also not be worthwhile developing large trials to investigate various treatment regimens for high-grade PIN found on Biopsy.

  • The diagnosis and reporting of adenocarcinoma of the prostate in core Needle Biopsy specimens
    Cancer, 1996
    Co-Authors: Jonathan I. Epstein
    Abstract:

    BACKGROUND. There has been relatively little written on the diagnosis and reporting of adenocarcinoma of the prostate diagnosed in core Needle Biopsy specimens. METHODS. This article reviews issues concerning diagnosing, grading, and quantification of prostate carcinoma in core Needle Biopsy specimens. RESULTS. The diagnosis of prostate carcinoma in core Needle Biopsy specimens is discussed, including the relative frequency and utility of various architecture, cytologic, and ancillary features. Grading of prostate carcinoma in core Needle Biopsy specimens is evaluated along with the relationship of core Needle Biopsy grade to corresponding radical prostatectomy grade. The relationship between the extent of carcinoma in core Needle Biopsy specimens to extent of tumor in the radical prostatectomy is summarized. Finally, this article summarizes articles supporting the use of high molecular weight cytokeratin in the diagnosis of adenocarcinoma of the prostate in core Needle Biopsy specimens. CONCLUSIONS. Pathologists are not only called upon to diagnose limited cancer in core Needle Biopsy specimens, but also to quantify and grade these cancers accurately. Issues relating to this pathologic evaluation are critical for physicians treating men with adenocarcinoma of the prostate.

Mi Kyung Shin - One of the best experts on this subject based on the ideXlab platform.

D P Colley - One of the best experts on this subject based on the ideXlab platform.

  • transthoracic Needle Biopsy of small pulmonary nodules
    Radiology, 1997
    Co-Authors: J L Westcott, N Rao, D P Colley
    Abstract:

    PURPOSE: To evaluate the diagnostic accuracy, complications, and usefulness of transthoracic Needle Biopsy of small pulmonary nodules. MATERIALS AND METHODS: Between January 1993 and January 1995, 302 patients underwent transthoracic Needle Biopsy of pulmonary lesions. Sixty-four lesions (in 62 patients) represented small nodules, defined as lesions of 15 mm or less maximum diameter. A total of 75 biopsies were performed in the 64 lesions. Approximately 90% of the biopsies were performed with computed tomographic guidance. RESULTS: There were 21 benign lesions and 43 cancers (36 primary, seven metastatic). Transthoracic Needle Biopsy findings were positive for cancer in 40 cases. In all three false-negative lesions, only one Biopsy was performed. There were 21 true-negative results and no false-positive results. Positive and negative predictive values were 100% and 88%, respectively. Pneumothorax occurred in 20 (27%) of 75 biopsies, but chest tube placement was necessary in only three cases (4%). Surgery ...

Related terms

Needle Biopsy - 15 days free trial to Access Experts & Abstracts